Bilibili Down Nearly 11%, on Pace for Lowest Close and Largest Percent Decrease Since November 2022 — Data Talk
Bilibili, Inc. Sponsored ADR Class Z (BILI) is currently at $11.89, down $1.45 or 10.86%
--Would be lowest close since Nov. 10, 2022, when it closed at $11.71
--On pace for largest percent decrease since Nov. 9, 2022, when it fell 12.02%
--Currently down five of the past six days
--Currently down three consecutive days; down 15.91% over this period
--Worst three day stretch since the three days ending Nov. 22, 2022, when it fell 16.72%
--Down 11.46% month-to-date; on pace for worst month since Aug. 2023, when it fell 20.66%
--Down 49.81% year-to-date; on pace for worst year on record (Based on available data back to March 28, 2018)
--Down 92.4% from its all-time closing high of $156.37 on Feb. 10, 2021
--Down 31.51% from 52 weeks ago (Nov. 30, 2022), when it closed at $17.36
--Down 59.28% from its 52-week closing high of $29.20 on Jan. 5, 2023
--Would be a new 52-week closing low
--Traded as low as $11.65; lowest intraday level since Nov. 10, 2022, when it hit $11.02
--Down 12.67% at today's intraday low; largest intraday percent decrease since Dec. 12, 2022, when it fell as much as 14.13%
All data as of 2:36:15 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
November 29, 2023 14:55 ET (19:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
Undervalued by 25% and Yielding 5%, This Stock Is a Buy
-
Can AI Predict Future Stock Returns?
-
The Best Energy Stocks to Buy Now
-
10 Undervalued Wide-Moat Stocks
-
Obesity Drugs: Can New Firms Take Market Share From Eli Lilly and Novo Nordisk?
-
New 4-Star Stocks
-
Intel Fair Value Left Unchanged Despite Qualcomm Takeover Talk